- Coordinator
- Scienta Lab, France
- Runs
- 1 December 2025 to 30 November 2027
- Status
- Running
- EU funding
- €2.5m
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 101247838
What the project is doing
In the project's own words, from its summary on CORDIS.
The immune system and its disorders are particularly complex to model, posing significant challenges for drug development. Due tothe limited representativeness of preclinical models, nearly half of clinical trial failures in immunology and inflammation stem frominsufficient efficacy. The rise of artificial intelligence capabilities offers a transformative opportunity to address this issue. With the support of the EICAccelerator project, France-based start-up Scienta Lab aims to develop a proprietary multimodal foundation model speciallydesigned for immunology and inflammation.
This advanced AI technology will enhance traditional preclinical approaches byvalidating the efficacy of new assets at the preclinical stage. By improving clinical trial success rates of innovative best-in-class assets,this innovation paves the way for precision medicine in immunology and inflammation.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Scienta Lab | Gif-Sur-Yvette | France | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI